These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30460422)

  • 1. MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity.
    Skála M; Hanousková B; Skálová L; Matoušková P
    Arch Toxicol; 2019 Jan; 93(1):1-9. PubMed ID: 30460422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.
    Koturbash I; Tolleson WH; Guo L; Yu D; Chen S; Hong H; Mattes W; Ning B
    Biomark Med; 2015; 9(11):1153-76. PubMed ID: 26501795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity:
    Boen HM; Cherubin M; Franssen C; Gevaert AB; Witvrouwen I; Bosman M; Guns PJ; Heidbuchel H; Loeys B; Alaerts M; Van Craenenbroeck EM
    JACC CardioOncol; 2024 Apr; 6(2):183-199. PubMed ID: 38774014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence.
    Korzeniowska K; Jankowski J; Cieślewicz A; Jabłecka A
    Ther Clin Risk Manag; 2019; 15():1095-1110. PubMed ID: 31564887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs in Anticancer Drugs Hepatotoxicity: From Pathogenic Mechanism and Early Diagnosis to Therapeutic Targeting by Natural Products.
    Atteia HH
    Curr Pharm Biotechnol; 2024; 25(14):1791-1806. PubMed ID: 38178678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets.
    Fa HG; Chang WG; Zhang XJ; Xiao DD; Wang JX
    Acta Pharmacol Sin; 2021 Apr; 42(4):499-507. PubMed ID: 32694762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNAs associated to anthracycline-induced cardiotoxicity in women with breast cancer: A systematic review and pathway analysis.
    Pereira JD; Tosatti JAG; Simões R; Luizon MR; Gomes KB; Alves MT
    Biomed Pharmacother; 2020 Nov; 131():110709. PubMed ID: 32937248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer.
    Broberg AM; Geisler J; Tuohinen S; Skytta T; Hrafnkelsdóttir ÞJ; Nielsen KM; Hedayati E; Omland T; Offersen BV; Lyon AR; Gulati G
    Curr Heart Fail Rep; 2020 Dec; 17(6):397-408. PubMed ID: 32979150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotective effects of miR-34a silencing in a rat model of doxorubicin toxicity.
    Piegari E; Cozzolino A; Ciuffreda LP; Cappetta D; De Angelis A; Urbanek K; Rossi F; Berrino L
    Sci Rep; 2020 Jul; 10(1):12250. PubMed ID: 32704131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity.
    Yadi W; Shurui C; Tong Z; Suxian C; Qing T; Dongning H
    BMC Cardiovasc Disord; 2020 Feb; 20(1):43. PubMed ID: 32013934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Specific Circulating MicroRNA Cluster Is Associated to Late Differential Cardiac Response to Doxorubicin-Induced Cardiotoxicity
    Ruggeri C; Gioffré S; Chiesa M; Buzzetti M; Milano G; Scopece A; Castiglioni L; Pontremoli M; Sironi L; Pompilio G; Colombo GI; D'Alessandra Y
    Dis Markers; 2018; 2018():8395651. PubMed ID: 30627229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs in Cancer Treatment-Induced Cardiotoxicity.
    Pellegrini L; Sileno S; D'Agostino M; Foglio E; Florio MC; Guzzanti V; Russo MA; Limana F; Magenta A
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32192047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy.
    Su X; Zhang X; Liu W; Yang X; An N; Yang F; Sun J; Xing Y; Shang H
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):929-942. PubMed ID: 34375726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a.
    Han D; Wang Y; Wang Y; Dai X; Zhou T; Chen J; Tao B; Zhang J; Cao F
    Circ Res; 2020 Jul; 127(4):e108-e125. PubMed ID: 32392088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-noncoding RNA MALAT1 sponges microRNA-92a-3p to inhibit doxorubicin-induced cardiac senescence by targeting ATG4a.
    Xia W; Chen H; Xie C; Hou M
    Aging (Albany NY); 2020 May; 12(9):8241-8260. PubMed ID: 32384281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin-induced cardiotoxicity.
    Beaumier A; Robinson SR; Robinson N; Lopez KE; Meola DM; Barber LG; Bulmer BJ; Calvalido J; Rush JE; Yeri A; Das S; Yang VK
    J Vet Intern Med; 2020 May; 34(3):1260-1271. PubMed ID: 32255536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of B-type natriuretic peptide as an early predictor of mortality in acutely poisoned patients with cardiotoxicities.
    Elgendy SA; Shoeib O; Elgharbawy D; Abo El-Noor MM; Kabbash A
    Toxicol Res (Camb); 2024 Aug; 13(4):tfae122. PubMed ID: 39105043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.
    Attanasio U; Di Sarro E; Tricarico L; Di Lisi D; Armentaro G; Miceli S; Fioretti F; Deidda M; Correale M; Novo G; Sciacqua A; Nodari S; Cadeddu C; Tocchetti CG; Palazzuoli A; Mercurio V
    Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of oligonucleotide- and protein/peptide-based therapeutics in the management of toxicant/stressor-induced diseases.
    Sadeghian I; Akbarpour M; Chafjiri FMA; Chafjiri PMA; Heidari R; Morowvat MH; Sadeghian R; Raee MJ; Negahdaripour M
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1275-1310. PubMed ID: 37688622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsa-miR-223-3p participates in the process of anthracycline-induced cardiomyocyte damage by regulating NFIA gene.
    Han X; Liu K; Gao F; Yang M; Wang F
    Open Med (Wars); 2023; 18(1):20230754. PubMed ID: 37533740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.